Abstract
This study aimed to evaluate in the Brazilian population, the genotypes and population frequencies of pharmacogenetic polymorphisms involved in the response to drugs used in treatment of acute lymphoblastic leukemia (ALL), and to compare the data with data from the HapMap populations. There was significant differentiation between most population pairs, but few associations between genetic ancestry and SNPs in the Brazilian population were observed. AMOVA analysis comparing the Brazilian population to all other populations retrieved from HapMap pointed to a genetic proximity with the European population. These associations point to preclusion of the use of genetic ancestry as a proxy for predicting drug response. In this way, any study aiming to correlate genotype with drug response in the Brazilian population should be based on pharmacogenetic SNP genotypes.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antimetabolites, Antineoplastic / pharmacokinetics
-
Antimetabolites, Antineoplastic / therapeutic use
-
Antineoplastic Agents / pharmacokinetics*
-
Antineoplastic Agents / therapeutic use
-
Biotransformation / genetics
-
Brazil
-
Gene Frequency
-
Genetic Loci
-
Genetic Markers
-
Genotype
-
Glucocorticoids / pharmacokinetics
-
Glucocorticoids / therapeutic use
-
HapMap Project
-
Humans
-
Mercaptopurine / pharmacokinetics
-
Mercaptopurine / therapeutic use
-
Methotrexate / pharmacokinetics
-
Methotrexate / therapeutic use
-
Polymorphism, Single Nucleotide*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
-
Racial Groups / genetics*
-
Regression Analysis
Substances
-
Antimetabolites, Antineoplastic
-
Antineoplastic Agents
-
Genetic Markers
-
Glucocorticoids
-
Mercaptopurine
-
Methotrexate